ICAP Clinical Trials Unit

ICAP 临床试验单位

基本信息

  • 批准号:
    10531542
  • 负责人:
  • 金额:
    $ 206.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-12-01 至 2027-11-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT While much has been achieved in the global HIV response, enormous challenges remain. Only 60% of people living with HIV (PLWH) access treatment and 1.7M new HIV infections were reported in 2018. In sub- Saharan Africa, elimination of mother to child transmission has stalled, men and youth lag behind in knowledge of HIV status, four of five new infections among adolescents occur among girls, and young women are twice as likely as men to have HIV. In the United States, annual new HIV infections have remained stable since 2013, with Black and Latino men who have sex with men (MSM) and women of color disproportionately affected. The ICAP Clinical Trials Unit (ICAP CTU), based at ICAP at Columbia University, will oversee research at five clinical research sites (CRSs): three in New York City (NYC), one in Eswatini, and one in Western Kenya. The NYC sites serve priority populations of great relevance to the current HIV epidemic, both living with and at risk for HIV, including Black and Latino MSM, women of color, young people, and people who inject drugs (PWID). The Eswatini and Kenya sites, in communities with some of the highest rates of new HIV infections in the world, have the capacity to engage children, adolescents, women at risk, men and key populations. Led by Drs. Wafaa El-Sadr and Jessica Justman, the ICAP CTU will pursue an innovative and comprehensive approach to HIV prevention and therapeutic research that tailors tools and strategies to the demographic characteristics, behavioral risks, co-morbidities and life circumstances of persons living with or at risk of acquiring HIV. Research undertaken by the CTU will be multi-faceted, accommodating the complexities of individual-level responses to interventions across numerous populations, and focused on advances that will support population-level reductions in HIV infection and improvements in quality of life and survival of PLWH. The specific aims of the ICAP CTU are (1) to advance the scientific agendas of all four NIH HIV networks by contributing to the development of effective HIV prevention, treatment and care interventions, with the goal of enhancing the lives of PLWH and stemming HIV transmission; (2) to build a strong CTU administrative structure that is outstanding in its capabilities and streamlined in its procedures, with efficiency, transparency, clear lines of authority, continuous quality improvement, full community engagement, and the highest performance standards; (3) to engage fully with the communities it serves through education, outreach and support of CRS community advisory boards; (4) to support core CRS technical functions, e.g., laboratory, pharmacy, regulatory, data management, quality assurance, training and staff development; and (5) to align the constituent CRSs into a cohesive and synergistic Unit that is truly pluripotent and that effectively advances the research agendas of the networks through development of new research concepts; participation in network protocols, scientific committees and working groups; and robust accrual and retention of diverse participants.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WAFAA M. EL-SADR其他文献

WAFAA M. EL-SADR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WAFAA M. EL-SADR', 18)}}的其他基金

ICAP Clinical Trials Unit
ICAP 临床试验单位
  • 批准号:
    10057719
  • 财政年份:
    2020
  • 资助金额:
    $ 206.43万
  • 项目类别:
ICAP Clinical Trials Unit
ICAP 临床试验单位
  • 批准号:
    10304864
  • 财政年份:
    2020
  • 资助金额:
    $ 206.43万
  • 项目类别:
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit
哥伦比亚艾滋病预防和控制伙伴关系临床试验单位
  • 批准号:
    10169016
  • 财政年份:
    2020
  • 资助金额:
    $ 206.43万
  • 项目类别:
Next Generation
下一代
  • 批准号:
    8639699
  • 财政年份:
    2013
  • 资助金额:
    $ 206.43万
  • 项目类别:
LINK4HEALTH: A Combination Strategy for Linkage and Retention, Swaziland
LINK4HEALTH:链接和保留的组合策略,斯威士兰
  • 批准号:
    8298777
  • 财政年份:
    2012
  • 资助金额:
    $ 206.43万
  • 项目类别:
LINK4HEALTH: A Combination Strategy for Linkage and Retention, Swaziland
LINK4HEALTH:链接和保留的组合策略,斯威士兰
  • 批准号:
    8484348
  • 财政年份:
    2012
  • 资助金额:
    $ 206.43万
  • 项目类别:
LINK4HEALTH: A Combination Strategy for Linkage and Retention, Swaziland
LINK4HEALTH:链接和保留的组合策略,斯威士兰
  • 批准号:
    8664342
  • 财政年份:
    2012
  • 资助金额:
    $ 206.43万
  • 项目类别:
LINK4HEALTH: A Combination Strategy for Linkage and Retention, Swaziland
LINK4HEALTH:链接和保留的组合策略,斯威士兰
  • 批准号:
    8797052
  • 财政年份:
    2012
  • 资助金额:
    $ 206.43万
  • 项目类别:
GH11-11108: TECHNICAL ASSISTANCE TO THE MOH FOR HIV SVC (PEPFAR)
GH11-11108:向卫生部艾滋病毒 SVC (PEPFAR) 提供技术援助
  • 批准号:
    8538252
  • 财政年份:
    2011
  • 资助金额:
    $ 206.43万
  • 项目类别:
GH11-11108: TECHNICAL ASSISTANCE TO THE MOH FOR HIV SVC (PEPFAR)
GH11-11108:向卫生部艾滋病毒 SVC (PEPFAR) 提供技术援助
  • 批准号:
    8775069
  • 财政年份:
    2011
  • 资助金额:
    $ 206.43万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 206.43万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 206.43万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 206.43万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 206.43万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 206.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了